Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent

Author's Avatar
Dec 02, 2020
Article's Main Image

Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD+Pharmaceuticals%2C+Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, titled “Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation” by the United States Patent & Trademark Office (USPTO). The patent is a continuation of U.S. patent application No. 15/558,094, which was granted as U.S. Patent No. 10,588,899 with claims for treating diabetes.